11 October 2021

ASX Announcement

Updated Investor Presentation

MELBOURNE Australia, 11 October 2021: Australian mid-clinical stage antiviral drug development company, Island Pharmaceuticals Ltd (ASX: ILA) is pleased to share its latest investor presentation.

In the coming week Island Pharmaceuticals management team will be participating in a non-deal roadshow in the US providing an update on the Company's progress. The presentation materials are attached.

Approved for release to the ASX by:

Dr Paul MacLeman
Executive Chairman
Isla Pharmaceuticals
info@islandpharmaceuticals.com

For further information, please contact:

Investors: Jane Lowe IR Department Mobile: +61 411 117 774 jane.lowe@irdepartment.com.au	**Media:** Juliana Roadley IR Department Mobile: +61 414 889 863 juliana.roadley@irdepartment.com.au

About Island Pharmaceuticals

Island is clinical-stage drug repurposing company, focused on the topical area of antiviral therapeutics for infectious diseases. Our lead asset is ISLA-101, a drug with a well-established safety profile, being repurposed for the prevention and treatment of dengue fever and other mosquito (or vector) borne diseases. The Company is advancing toward a Phase II clinical trial in dengue-infected subjects.

If ISLA-101 achieves FDA approval, and certain other criteria are met, Isla may be eligible to obtain a "Priority Review Voucher" at the time of FDA approval. This means that as well as getting approval to manufacture and sell ISLA-101, the Priority Review Voucher (PRV) would permit Island to expedite the FDA approval process for a new drug or sell the PRV in a secondary market.

Island encourages all current investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, whose contact info is housed on the Shareholder Services page of the Company's website.

Visit www.islandpharmaceuticals.com for more on Island.

ISLAND
PHARMACEUTICALS
Antiviral therapeutics

SOLVING URGENT VIRAL DISEASE THREATS

(ASX: ILA)
October 2021

DISCLAIMER

ISLAND PHARMACEUTICALS
Antiviral therapeutics

This presentation has been prepared by Island Pharmaceuticals Limited (ABN 641 183 842) (**Company** or **Island Pharmaceuticals**).

Not an offer or financial product advice

The Company is not licensed to provide financial product advice. This presentation is not and should not be considered, and does not contain or purport to contain, an offer or an invitation to sell, or a solicitation of an offer to buy, directly or indirectly any securities, to any person in any jurisdiction to whom or in which such offer or solicitation is unlawful nor shall it (or any part of it), or the fact of its distribution, form the basis of, or be relied on in connection with or act as any inducement or recommendation to enter into, any contract whatsoever relating to any securities. This presentation is for information purposes only and is not a prospectus, product disclosure statement, pathfinder document for the purposes of section 734(9) of the Australian Corporations Act 2001 (Cth) (**Corporations Act**) or other offer document under Australian law or the law of any other jurisdiction. This presentation does not constitute an invitation to apply for or purchase Securities and does not include any application form for Securities. This presentation does not constitute an advertisement for an offer or proposed offer of Securities. Neither this presentation nor anything contained in it shall form the basis of any contract or commitment and it is not intended to induce or solicit any person to engage in, or refrain from engaging in, any transaction. Nothing in this presentation constitutes legal, financial, tax or other advice. Recipients of the presentation should conduct their own investigation, evaluation and analysis of the business and other data and information set out in the presentation.

Financial data All dollar values are in Australian dollars ($ or A$) unless otherwise stated. Any financial data in this presentation is unaudited. Past performance The operating and historical financial information given in this presentation is given for illustrative purposes only and should not be relied upon as (and is not) an indication of the Company's views on its future performance or condition. Actual results could differ materially from those referred to in this presentation. You should note that past performance of the Group is not and cannot be relied upon as an indicator of (and provides no guidance as to) future Group performance.

Future performance

This presentation contains certain "forward-looking statements". The words "expect", "anticipate", "estimate", "intend", "believe", "guidance", "propose", "goals", "targets", "aims", "outlook", "forecasts", "should", "could", "would", "may", "will", "predict", "plan" and other similar expressions are intended to identify forward-looking statements. Any indications of, and guidance on, future operating performance, earnings and financial position and performance are also forward-looking statements. Forward-looking statements in this presentation include statements regarding the Company's future growth options, strategies and new products. Forward-looking statements, opinions and estimates provided in this presentation are based on assumptions and contingencies which are subject to change without notice, as are statements about market and industry trends, which are based on interpretations of current market conditions.

Forward-looking statements, including projections, guidance on future operations, earnings and estimates (if any), are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. No representation is given that the assumptions upon which forward looking statements may be based are reasonable. This presentation contains statements that are subject to risk factors associated with the Group's industry. These forward-looking statements may be affected by a range of variables which could cause actual results or trends to differ materially, including but not limited to earnings, capital expenditure, cash flow and capital structure risks and general business risks.

No representation, warranty or assurance (express or implied) is given or made in relation to any forward-looking statement by any person (including the Company). In particular, but without limitation, no representation, warranty or assurance (express or implied) is given that the occurrence of the events expressed or implied in any forward looking statements in this presentation will actually occur. Actual operations, results, performance or achievement may vary materially from any projections and forward-looking statements and the assumptions on which those statements are based. Any forward looking statements in this presentation speak only as of the date of this presentation.

Subject to any continuing obligations under applicable law, the Company disclaims any obligation or undertaking to provide any updates or revisions to any forward-looking statements in this presentation to reflect any change in expectations in relation to any forward-looking statements or any change in events, conditions or circumstances on which any such statement is based.

Nothing in this presentation will under any circumstances create an implication that there has been no change in the affairs of the Group since the date of this presentation.

COMPANY OVERVIEW

ISLAND
PHARMACEUTICALS
Antiviral therapeutics

ISLAND AT A GLANCE

ISLAND PHARMACEUTICALS
Antiviral therapeutics

Island Pharmaceuticals (ASX: ILA) is a mid clinical-stage drug repurposing company, focused on the rapid development of antiviral therapeutics for infectious diseases

Island Pharmaceuticals listed on the ASX following oversubscribed A$7.5m IPO in April 2021

Island's drug repurposing strategy enables rapid and efficient development of antiviral therapies

Initial focus is on mosquito borne diseases with a Phase II lead program in Dengue fever.

SOLVING URGENT VIRAL DISEASE THREATS

ISLAND PHARMACEUTICALS
Antiviral therapeutics







Cost Estimates	Mar 2020	World bank $10 Trillion loss in GDP 2020 - 21	IMF $28 Trillion	JAMA Network $16 Trillion **
		Sep 2020	Oct 2020	Aug 2021
Deaths	3.26 million cases 233,000 deaths			4,220,696 deaths

* Sources: https://jamanetwork.com/journals/jama/fullarticle/2771764 https://www.oecd.org/coronavirus/policy-responses/risks-that-matter-2020-the-long-reach-of-covid-19-44932654/

DRUG REPURPOSING MARKET

ISLAND PHARMACEUTICALS
Antiviral therapeutics

The global market for drug repurposing will grow from nearly **$24.4 billion** in 2015 to nearly **$31.3 billion** by 2020*

Bringing a new medicine or vaccine to market may now cost as much as **US$2.8 billion** on average and require between 10 and 15 years' work

Advantages of a drug repurposing approach for antiviral drug discovery

- Low cost and less time-consuming
- Possibility to go directly to phase II clinical trials
- Potential for combination strategies
- Formulations and manufacturing chains are already established for de-risked manufacturing

Source: https://www.bccresearch.com/market-research/pharmaceuticals/drug-repurposing-markets-report.html

THE BENEFITS OF DRUG REPURPOSING

ISLAND PHARMACEUTICALS
Antiviral therapeutics



***De novo* Drug Discovery and Development**
- Low Success Rate
- Huge Cost and Time-consuming Development

Drug Repurposing
- Known Drug Safety
- Reduced Pharmacokinetic Uncertainty

Drug Repurposing

ISLA-101 REPURPOSED DRUG

DRAMATICALLY REDUCES DEVELOPMENT TIME, RISK AND COST

ISLAND PHARMACEUTICALS
Antiviral therapeutics

ISLA-101, originally a cancer drug

Originally identified by Johnson & Johnson and studied as a potential chemotherapy

Demonstrated as safe in humans

Used in 45 clinical studies (including Phase II & III) demonstrating an excellent safety profile in thousands of patients including children

Strong regulatory history and acceptance

Multiple regulatory jurisdictions have reviewed ISLA-101 as having a well established safety profile

Speed to market & early revenue potential

Clearance of early phases allows many years to be saved in drug development and quick path to market

Capitalising on millions spent

Funds and time spent to date reduce risk and allow for immediate move to Phase II study

KEY COLLABORATIONS & ALLIANCES

SUPPORTING FUTURE PIPELINE DEVELOPMENT

ISLAND PHARMACEUTICALS
Antiviral therapeutics

MONASH University	Research Collaboration Agreement to screen thousands of known molecules against host targets building upon the Fenretinide (ISLA-101) discovery sourced from these laboratories that the Company has licensed for use against Flaviviruses
Griffith University – Griffith Institute for Drug Discovery	Research and development collaboration with Griffith University to screen for active anti-viral molecules in a rational repurposing strategy. The small molecule libraries for Drug Discovery (GRIDD) Compounds Australia facility, using highly sensitive assays.
COMPOUNDS AUSTRALIA	Research collaboration agreement signed with Australia's largest drug library containing approximately four and a half thousand molecules that can be searched for drug re-purposing and pipeline development
United States Army	Cooperative Research and Development Agreement (CRADA) with the US Army in preparation for Phase II clinical study for ISLA-101
Catalent	Supply agreement with Catalent for manufacture of Fenretinide softgels for dengue fever trial participants
NIH National Cancer Institute	Right to reference National Cancer Institute IND for ISLA-101

INITIAL COLLABORATION

LICENSED FOR USE AGAINST FLAVIVIRUSES AND PIPELINE EXPANSION

ISLAND PHARMACEUTICALS
Antiviral therapeutics

Monash University

- Isla US initially licensed intellectual property (IP) created by Monash University. IP was produced as part of a research project undertaken by Monash University that led to a drug candidate, ISLA-101 for repurposing. ISLA-101 is indicated for the prevention and/or treatment of mosquito borne viruses.
- Prof. David Jans at Monash Biomedicine Discovery Institute focusses on viruses of medical significance, seeking to explore virus-human protein interactions in disease, and how this can be exploited for therapeutic intervention.
- Our expanded collaboration with Prof. David Jans underpins our pipeline development strategy to pivot quickly to develop drugs as urgent emerging viral disease issues arise again.

MONASH University

Prof. David Jans

RECENTLY SIGNED COLLABORATION

ACCELERATE PIPELINE DEVELOPMENT

ISLAND PHARMACEUTICALS
Antiviral therapeutics

On 23 August 2021
Island Pharmaceuticals (ASX: ILA) announced a Anti-Viral Molecule Screening Collaboration with Griffith University.

- The new drug research collaboration focuses on repurposing small molecules with known clinical histories as new anti-viral agents.
- Accessing the small molecule libraries at Griffith Institute for Drug Discovery (GRIDD) and Compounds Australia facility, using highly sensitive assays.
- Utilises highly sensitive screening technology to assist in accelerating drug repurposing strategies
- Enhances Island's drug development pipeline, focused on advancing preventative or therapeutic drugs for existing and emerging viral threats beyond mosquito borne viruses

Griffith UNIVERSITY
Griffith Institute for Drug Discovery

Prof. Ron Quinn
Griffith University

MENZIES HEALTH INSTITUTE QUEENSLAND
Griffith UNIVERSITY

Prof. Suresh Mahalingam
Health Institute Queensland (MHIQ)

BOARD, MANAGEMENT & SCIENTIFIC BOARD

EXTENSIVE EXPERTISE IN DRUG REPURPOSING AND DEVELOPMENT, INFECTIOUS DISEASES AND COMMERCIAL TRANSACTIONS.

ISLAND PHARMACEUTICALS
Antiviral therapeutics

MANAGEMENT TEAM & BOARD OF DIRECTORS

Dr. Paul MacLeman
Executive Chair

Dr. David Foster
CEO & Executive Director

Dr. Anna Lavelle
Non-Executive Director

Mr. Al Hansen
Non-Executive Director

Dr. David Brookes
Non-Executive Director

SCIENTIFIC ADVISORY BOARD

Assoc. Prof. Leigh Farrell

Prof. Stephen Thomas MD

Dr. Simon Tucker

CORPORATE SNAPSHOT

ISLAND PHARMACEUTICALS
Antiviral therapeutics

ISSUED CAPITAL		
Shares issued in IPO		30,000,000
Prior Shares on issue 50,968,468		50,968,468
Total number of shares on issue		80,968,468
MARKET CAPITALISATION		
IPO price (13th April 2021)		$0.25
Share price (as at 30 Sept 2021)		$0.34
Market capitalisation		$27.5M
Cash (30 June 2021)		$6.5M
SIGNIFICANT SHAREHOLDERS		
Dr William J Garner	21,090,605	27.13%
Mr Albert Hansen (Kesa Partners)	10,837,367	13.38%
Dr David C Foster	5,146,829	6.36%
Mr Jason A Carroll	4,050,000	5.32%




ILSA-101
ISLAND
PHARMACEUTICALS
Antiviral therapeutics

ISLA-101

BRINGING ITS PLATFORM IN A PILL TO MARKET

ISLAND PHARMACEUTICALS
Antiviral therapeutics

Island has repurposed **ISLA-101,** an antiviral oral drug to treat mosquito-borne viruses (e.g. dengue fever / Zika) and intends to complete Phase II studies with a significantly de-risked clinical program

Warming global climates are accelerating the presence of mosquito-borne viruses that can cause deaths in the US, Europe and Australia

KEY STRENGTHS

ISLAND PHARMACEUTICALS
Antiviral therapeutics

Initially targeting dengue diseases with unmet need

Targeting diseases, starting with dengue fever, with a significant unmet medical need and growing economic burden

Drug repurposing strategy

Lead compound, ISLA-101, has been in 45 clinical trials demonstrating an excellent safety profile in thousands of patients

Phase II ready asset

Repurposing can save tens of millions of dollars and up to a decade of development time usually required to commercialise a new drug

Promising results to date

Results in aggressive animal and human cellular models of dengue fever and Zika infections as well as data in a range of other flaviviruses

Commercial upside

Potential 'platform in a pill' to treat tropical diseases. Approval of ISLA-101 by the US FDA could see company claim a Priority Review Voucher

Highly experienced team

Experienced Board, Management Team & Scientific Advisory Board with extensive expertise in drug repurposing, infectious diseases and commercial transactions

WHY DENGUE DISEASES?

SIGNIFICANT UNMET NEED FOR DISEASE WITH INCREASING INCIDENCE

ISLAND PHARMACEUTICALS
Antiviral therapeutics



- Significant unmet need (3.9 billion people at risk*)
- Increasing spread to US, EU and Australia
- ISLA-101 has both therapeutic and prophylactic potential
- Strong animal and human model results
- First claim then spring board into other viral diseases
- Priority Review Voucher eligibility

* http://www3.weforum.org/docs/WEF_The_Global_Risks_Report_2021.pdf

MOSQUITO BORNE DISEASES

MORE PATIENTS, HIGH COSTS, POTENTIALLY A LIFETIME OF ISSUES FOR PATIENTS

ISLAND PHARMACEUTICALS
Antiviral therapeutics

Primary target

Mosquito-borne flaviviruses



- Dengue fever
- West Nile virus
- Zika virus
- Yellow fever virus
- Japanese Encephalitis virus
- Others

Can result in life threatening conditions

- Haemorrhagic fever
- Shock syndrome
- Encephalitis
- Paralysis
- Congenital defects
- Hepatitis
- Hepatic failure

390m*

Estimated global cases per year (dengue fever only)

US$8.9B*

Estimated impact to the economy from dengue fever

* http://www3.weforum.org/docs/WEF_The_Global_Risks_Report_2021.pdf

FLAVIVIRUSES BECOMING GLOBAL

WARMING GLOBAL CLIMATES ARE EXPANDING SPREAD BEYOND THE TROPICS*

ISLAND PHARMACEUTICALS
Antiviral therapeutics



Flaviviruses are spreading outside the tropics:

1. Florida, US
2. Mediterranean, EU
3. QLD, Australia

Growing issue for countries hosting US military bases

4. Singapore
5. Saudi Arabia
6. Japan
7. South Korea

* Nature Microbiology | VOL 5 | June 2020 | 796–812 | www.nature.com/naturemicrobiology

LIMITED AVAILABLE SOLUTIONS

HIGHLY PREVALENT DISEASES WITH UNMET MEDICAL NEED

ISLAND PHARMACEUTICALS
Antiviral therapeutics

	Dengue fever	West Nile	Zika Virus	Yellow fever	Japanese Encephalitis	
Worldwide prevalence	390 million	n/a	Up to 1.5 million	130,000	70,000	Viral diseases are a leading cause of hospitalisation and death
Effective drug therapy	No	No	No	No	No	Antimalarial drugs market is expected to reach US$1B in 2026 providing guidance to potential market size*
Vaccine	Limited	No	No	Limited	Limited	**Vaccine development potentially can exacerbate symptoms from infections by different strains**

* **Saving Lives, Buying Time: Economics of Malaria Drugs in an Age of Resistance,** Economics of Malaria Drugs in an Age of Resistance Institute of Medicine (US) Committee on the Economics of Antimalarial Drugs; Editors: Kenneth J. Arrow, Claire Panosian, and Hellen Gelband. Washington (DC): National Academies Press (US); 2004.

ISLA-101 PREVENTS VIRAL REPLICATION

ISLA-101 INHIBITS PROPAGATION OF FLAVIVIRUSES*



- To replicate, the virus needs to hijack the nucleus of the host cell
- Studies demonstrated ISLA-101 prevents this so prevents virus replication
- Same mechanism of action for a therapeutic or prophylactic – either before or after exposure to the virus

ISLA-101 targets protection of the nucleus

Viral replication

- Source: *Jans & Martin; Adv Exp Med Biol. 2018;1062:199-213. doi: 10.1007/978-981-10-8727-1_15.

ISLA-101 BROAD ACTIVITY EVIDENT

DEMONSTRATED ACTIVITY AGAINST FLAVIVIRUSES IN MULTIPLE MODELS OF INFECTION

- In *in-vitro* models using fresh human cells, ISLA-101 has demonstrated broad anti-viral activity
- In animal models, ISLA-101 is protective in dengue fever and Zika
- In extremely lethal animal models, ISLA-101 was shown to prevent death in 70% of subjects
- Increasing concentrations of ISLA-101 prevent death induced by an otherwise lethal dengue fever infection

SAFETY PROFILE OF DRUG ESTABLISHED

45 HUMAN CLINICAL STUDIES OF ISLA-101 COMPLETED IN OTHER INDICATIONS

ISLAND PHARMACEUTICALS
Antiviral therapeutics



Verified as safe in humans by multiple regulators in other clinical indications

ISLA-101 ACCELERATED TIMELINE FY22

LEVERAGING THE ESTABLISHED SAFETY PROFILE OF ISLA-101

ISLAND PHARMACEUTICALS
Antiviral therapeutics

Millions of dollars and years saved

Significant near-term, value accretive news flow anticipated during development

Completed prior to IPO	FY21	H1 FY22	H2 FY22	H1 FY23
Discovery	ASX IPO	Sign SUNY Clinical Trial Agreement	Open IND	Trial read out
Pre-clinical testing	US Patent	Engage CRO	Screening subjects for enrolment in trial	Meeting with FDA
Extensive Phase I safety data held on file	Australian Patent	File Investigational New Drug (IND) application	First patient in Phase II trial	
ISLA-101 to move straight to Phase II trials	API source secured			
	Walter Reed conducting control arm			

DRUG DEVELOPMENT PIPELINE

ISLAND PHARMACEUTICALS
Antiviral therapeutics

Program	Indication	Stage of Development				
		Preclinical	Phase I	Phase II	Phase III	FDA Review
ISLA-101	Dengue (PEACH)			To be initiated		
	Other mosquito (or vector) borne diseases					
Monash Collaboration	TBD					
Griffith Collaboration	TBD					

WHAT IS A CHALLENGE STUDY?

HUMAN CHALLENGE STUDIES HAVE CONTRIBUTED VITAL SCIENTIFIC KNOWLEDGE

ISLAND PHARMACEUTICALS
Antiviral therapeutics

- In human challenge trials, participants are intentionally challenged with an infectious disease organism.
- Challenge organism may be close to wild-type and pathogenic, adapted and/or attenuated from wild-type with less or no pathogenicity.
- Human challenge studies have been conducted over hundreds of years and have contributed vital scientific knowledge that has led to advances in the development of drugs and vaccines.
- Clinical trials are designed and conducted in a manner that minimizes risks to human subjects while maximizing the potential for benefit.

Island Pharmaceuticals will work with Walter Reed Army Medical Center on its **"virus challenge model" -** Dengue Human Infection Model (DHIM) for its Phase II clinical study for ISLA-101.

CLINICAL DEVELOPMENT PROGRAM

INITIAL FOCUS ON BRINGING A DENGUE FEVER DRUG TO MARKET

ISLAND PHARMACEUTICALS
Antiviral therapeutics

Activities to derisk Island's Investigational New Drug (IND) application

Shortened timeframe for Phase II trials

- Agreement with the National Cancer Institute in the US to use a previously approved IND Application
- Cooperative Research and Development Agreement (CRADA) with the US Army in preparation for its Phase II clinical study for ISLA-101
- Supply agreement in place with Catalent for manufacture of Fenretinide 100 mg softgels for dengue fever trial participants
- Agreement in place with Camargo to develop a nonclinical, clinical, clinical pharmacology and biopharmaceutics strategy and program

Potential expansion to other tropical diseases (eg Zika/West Nile)

Opportunity for Priority Review Voucher as a value accretion multiplier

PHASE II DENGUE (PEACH) TRIAL STUDY IN DETAIL

ISLAND PHARMACEUTICALS
Antiviral therapeutics

"PEACH" STUDY- A PHASE II, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY FOR THE PROPHYLACTIC EXAMINATION OF AN ANTIVIRAL IN A DENGUE CHALLENGE MODEL

Phase II trial protocol

Up to 4 cohorts/4 arms

Inclusion

- Healthy subjects
- Age 18-45
- Willing to use contraception for the duration of the study
- Informed consent

Exclusion

- Female: pregnant or lactating
- Prior infection with HIV, HCV, Flaviviruses
- Current, or a history of, auto-immune disease

Primary endpoint

- Assess the prophylactic effect of ISLA 101 on fever, clinical symptoms, laboratory abnormalities and viremia after challenge with DENV-1-LVHC

Secondary endpoints

- Characterise the clinical, immunologic and virologic responses following ISLA 101 after challenge with DENV-1-LVHC
- Assess the safety of ISLA 101 in the challenge with DENV-1-LVHC



The study will be run at SUNY Upstate Medical University Syracuse, New York

PRIORITY REVIEW VOUCHER ELIGIBILITY

ISLAND PHARMACEUTICALS
Antiviral therapeutics

- ISLA-101 is eligible for Neglected Tropical Disease designation for the treatment of dengue fever
- This designation means ISLA-101 has the opportunity to be awarded a Priority Review Voucher (PRV) from the FDA if first approved for dengue fever or Zika
- A PRV grants the holder an accelerated six month review of a drug application by the FDA
- As PRVs are transferable, they are highly valuable to drug development companies with numerous precedents for sales to biotech and pharma companies

Recent PRV acquisitions

Date	Acquired by	Value
Q3 2019	Astra Zeneca	US$95m
Q4 2019	Confidential	US$95m
Q1 2020	Vifor Pharma	US$111m
Q3 2020	Merck	US$100m
Q4 2020	Abbvie	US$95m
Q4 2020	United Therapeutics	US$105m
Q1 2021	Alexion	US$100m
Q3 2021	Kedrion S.p.A	US$105m
Q1 2022	Undisclosed	$US105m
Average		**US$101m**

COMMERCIAL OPPORTUNITY

ISLAND PHARMACEUTICALS
Antiviral therapeutics

Prophylactic for travelers | **Military** | **National outbreaks** | **Government Stockpiles** | **Priority Review Voucher**

Tropical area travellers opportunity:
- Annual market many millions of individuals (military opportunity not included)
- Predictable outbreaks will drive sales
- Increasing numbers of countries due to global warming

Military opportunity:
- Isla is partnering with Army (CRADA in place) for Phase IIa clinical trial in Dengue Fever
- We will pursue a contract with the military as we get closer to approval

Endemic area opportunity:
- Many millions of patients in Central and South America
- Potential for sales for disease suppression and treatment during outbreaks
- Potential for endemic countries to establish and maintain drug stockpiles as happens with influenza

David Foster
Chief Executive Officer & Executive Director
david@islapharma.com

www.islapharma.com
Registered office: Suite 201, 697 Burke Rd, Camberwell VIC 3124, Australia

Island Pharmaceuticals Limited
ACN 641 183 842

Appendix

INTELLECTUAL PROPERTY

ISLAND PHARMACEUTICALS
Antiviral therapeutics

In-licensed patents	• PCT/AU2014/050017, filed 16 April 2014 • National stage applications underway/filed in Australia, Brazil, Canada, Singapore & US • Issued patents in Australia, Brazil, Singapore and US • Potential for new patents
Available knowhow	• Investigator Brochure from National Cancer Institute and Walter Reed Army Research Hospital • Right of cross reference to existing IND from NCI and Walter Reed Army Research Hospital • Rights to Walter Reed control volunteer data
New IP	• Likely identify inventions to patent during clinical trials to expand Island Pharma portfolio
Licenses	• Monash license • Single digit royalties, deferred milestones until Phase III
New leads	• Research collaboration program

ISLA101 PROTECTS HUMAN CELL CULTURE FROM DENGUE



- In pre-clinical work, ISLA-101 has been specifically shown to suppress the ability of dengue to infect human cells
- **Potential role as both preventive and treatment, enabling multiple markets**

- Vero cells cultured in the presence of different agents and infected with Dengue Virus-2.
- Viral RNA from culture from media measured as an indication of virus titer. Fraser et al. J. Infect. Dis 2014

PROTECTS CELLS FROM INFECTION BY MANY VIRUSES

ISLAND PHARMACEUTICALS
Antiviral therapeutics

Proven in:

- Dengue 1
- Dengue 2
- Dengue 3
- Dengue 4
- Zika
- West Nile
- Chikungunya
- Yellow Fever

Zika



Chikungunya



- Importantly, ISAL-101 showed very a strong dose response in decreasing viral load
- This has established commencement dosing for Phase IIa Dengue challenge trial

Wang et all BBRC 2017 and WO 2014/169355

PREVENTS ANIMAL DEATHS FROM LETHAL DENGUE

ISLAND PHARMACEUTICALS
Antiviral therapeutics

Isla- 101 has also been shown to be protective in animal models of both dengue and Zika Virus.



Survival curve showing protection from lethal dengue change by Increasing dose of ISLA101 (mouse model).
Fraser et al. J. Infect. Dis 2014

PROVIDES PROTECTION AGAINST INFECTION OF HUMAN CELLS



- Freshly isolated human PBMCs protected from infection with dengue 2 virus in a dose dependent fashion

Fraser et al. J. Infect. Dis 2014

PLATFORM STRATEGY: *MULTIPLE SHOTS ON GOAL*

ISLAND PHARMACEUTICALS
Antiviral therapeutics

TARGETS

- Tropical diseases with no existing therapies
- Prophylactic or therapeutic trial potential



BOARD OF DIRECTORS

ISLAND PHARMACEUTICALS

utics

ISLAND IS LED BY A HIGHLY CAPABLE, EXPERIENCED MANAGEMENT TEAM, BOARD OF DIRECTORS AND SCIENTIFIC ADVISORY BOARD WITH EXTENSIVE EXPERTISE IN DRUG REPURPOSING AND DEVELOPMENT, INFECTIOUS DISEASES AND EXECUTING SUCCESSFUL COMMERCIAL TRANSACTIONS.

Dr. Paul MacLeman
Executive Chair

- Decades of experience across the life sciences sector, including veterinary practice, pharmaceutical development and manufacturing, biotechnology, diagnostics and finance.
- Expertise in capital raising, business development, technology commercialisation, and drug development. He has founded life sciences start-ups in the biologics area and worked in investment banking.
- Previously served as Managing Director and/or CEO of several VC funded, ASX, NASDAQ and TSX listed companies. Paul is the current Chairman of AdAlta Limited (ASX:1AD). Fellow of the Australian Institute of Company Directors.

Dr. David Foster
CEO & Executive Director

- 20+ years experience in life sciences representing pharmaceutical, biotherapeutic and diagnostic companies, while in private legal practice.
- Served as intellectual property counsel at Medarex, a biotherapeutics company, acquired by Bristol-Myers Squibb.
- Co-founded Roberts Foster LLP - a tech focused law firm, BioNTX a regional life science trade association, & multiple private biotechnology companies.
- Board member of BioNTX & private biotechnology companies, and is a Member of Australian Institute of Company Directors.
- Ph.D. from The University of Texas Southwestern Medical Center & J.D. from Golden Gate University School of Law.

Dr. Anna Lavelle
Non-Executive Director

- Chair of Medicines Australia; Chair Avatar Pty Ltd,; previously CEO and Executive Director of AusBiotech Ltd.; Executive at the Australian Red Cross Blood Service; NED, Hemideina Pty Ltd, Cyban Pty Ltd, Sementis Pty Ltd., Research Australia, the Agricultural Biotechnology Council of Australia and the Advisory Board for the School of Biological Sciences at Monash University.
- Chaired, or has been a member of various Federal and State government advisory committees, including National Health and Medical Research Council. PhD in Genetics from the University of Melbourne, and is a Fellow of the Australian Academy of Technological Sciences and Engineering.

Mr. Al Hansen
Non-Executive Director

- Managing Partner. KESA Partners. Decades of experience in healthcare and investment, including Managing Director of Signet Healthcare Partners, serving on investee companies as Chairman, Director and Interim CEO of pharmaceutical companies and CROs.
- Substantial senior investment banking experience at firms such as Darby Overseas Investments, Dillon Read and E. F. Hutton. Former Director - Corporate Finance US Treasury, and retired Captain, U.S Army Special Forces.

Dr. David Brookes
Non-Executive Director

- Extensive experience in the health and biotechnology industries, including Board positions in numerous ASX listed biotechnology companies, including as Non-Executive Chairman of genomics solutions company, RHS Ltd, which was acquired by PerkinElmer Inc.
- Currently Non-Executive of Chairman of Anatara Lifesciences Ltd (ASX:ANR) and of Dominion Minerals Limited (ASX:DLM formerly Factor Therapeutics ASX:FTT). Non-Executive Director of TALI Digital Limited (ASX:TD1)
- MBBS (Adelaide), Fellow of the Australian College of Rural and Remote Medicine and a Fellow of the Australian Institute of Company Directors.

SCIENTIFIC ADVISORY BOARD

HEAVYWEIGHT ADVISORS WITH GLOBAL PEDIGREE

ISLAND PHARMACEUTICALS
Antiviral therapeutics

Assoc. Prof. Leigh Farrell

- Former Vice President of Business Development at Biota Pharmaceuticals (now Vaxart)
- Extensive operational and advisory experience in antiviral drug development including for the military
- Previously Chief Operating Officer, d3 Medicine, General Manager then CEO, GeneShears Pty Ltd: Research Manager Johnson & Johnson Research Pty Ltd; Associate Director, GBS Venture Partners
- Member, the Australian Research Advisory Council and the Victorian Biotechnology Advisory Council

Dr. Simon Tucker

- Former Vice President of Research at Biota Pharmaceuticals (now Vaxart), where he was responsible for their entire intellectual property and research portfolio and oversaw the development of the now FDA approved influenza drug Relenza, one of only three anti-virals for influenza
- Decades of experience in pharmaceutical research and development and management as CEO of both Jumpstart Fertility Inc. and Continuum Biosciences Inc
- Previously worked at GD Searle, USA, helping make key discoveries leading to the development of a treatment for HIV infection

Prof. Stephen Thomas MD

- International leadership role as Lead Principal Investigator for Pfizer/BioNTech global Phase III COVID-19 vaccine trial now being deployed globally
- Prof. Thomas is a world-renowned virologist and vaccinologist and has authored numerous papers and articles on dengue fever, Zika and many other infectious diseases
- Chief, Division Of Infectious Diseases, New York Upstate Medical University; Professor of Medicine, Professor of Microbiology & Immunology, and Infectious Diseases physician-scientist from the State University of New York (SUNY), Upstate Medical University; Chief, Division of Infectious Diseases and Director, Institute for Global Health and Translational Science (IGHTS)
- Twenty years in the U.S. Army Medical Corps serving at the Walter Reed Army Institute of Research (WRAIR)

David Foster
Chief Executive Officer & Executive Director
david@islapharma.com

www.islapharma.com
Registered office: Suite 201, 697 Burke Rd, Camberwell VIC 3124, Australia
Approved for release by Paul MacLeman

Island Pharmaceuticals Limited
ACN 641 183 842